{"id":"W4295592704","doi":"10.1016/j.esmoop.2022.100572","title":"The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Eli Lilly Japan; Medtronic Japan; Chugai Pharmaceutical; Genentech; Taiho Pharmaceutical; Sanofi; GlaxoSmithKline; Teijin Pharma; Amgen; Pfizer; Les Laboratories Pierre Fabre; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Ono Pharmaceutical","keywords":"Osimertinib; Medicine; Oncology; Internal medicine; Adjuvant; Hazard ratio; Stage (stratigraphy); Lung cancer; Clinical endpoint; Adjuvant therapy; Disease; Erlotinib; Cancer; Confidence interval; Clinical trial; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1699082,0.001297961,0.000919283,0.00248352,0.003281305,0.002640245,0.001487109,0.002717849,0.001732492],"category_scores_gemma":[0.0942704,0.0007836873,0.00188592,0.001555168,0.006951727,0.003436518,0.01168455,0.003288699,0.000279485],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006481504,"about_ca_system_score_gemma":0.01464368,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002029891,"about_ca_topic_score_gemma":0.001931901,"domain_scores_codex":[0.8138433,0.1614087,0.01001529,0.002586899,0.006942463,0.005203403],"domain_scores_gemma":[0.8902484,0.08842262,0.003939332,0.001901642,0.01255706,0.002931001],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"qualitative","study_design_gemma":"qualitative","study_design_scores_codex":[0.001375608,0.0004747951,0.03140432,0.01514946,0.0004869481,0.00137733,0.6911616,0.003212912,0.01013732,0.01226084,0.01524077,0.2177181],"study_design_scores_gemma":[0.0003212742,0.002110318,0.0368773,0.01380619,0.0004311431,0.002183336,0.8443165,0.005769696,0.005113603,0.01752779,0.07104169,0.0005011929],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.838119,0.01065177,0.04673818,0.05411856,0.00147538,0.01871695,0.0007088004,0.00008281601,0.02938848],"genre_scores_gemma":[0.9475611,0.005155685,0.03096983,0.004896651,0.000205853,0.01013968,0.000231561,0.00002763103,0.0008120593],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.1699082,"threshold_uncertainty_score":0.8985713,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0247869129713328,"score_gpt":0.3389535306115541,"score_spread":0.3141666176402214,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}